image
Healthcare - Medical - Devices - NASDAQ - GB
$ 52.1
-0.42 %
$ 2.83 B
Market Cap
121.16
P/E
1. INTRINSIC VALUE

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS.[ Read More ]

The intrinsic value of one LIVN stock under the base case scenario is HIDDEN Compared to the current market price of 52.1 USD, LivaNova PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart LIVN

image
FINANCIALS
1.15 B REVENUE
12.89%
-68.5 M OPERATING INCOME
-129.98%
17.5 M NET INCOME
120.35%
74.9 M OPERATING CASH FLOW
7.17%
-40.3 M INVESTING CASH FLOW
-5.03%
21.5 M FINANCING CASH FLOW
-92.33%
318 M REVENUE
-0.14%
35.6 M OPERATING INCOME
-23.42%
33 M NET INCOME
101.76%
51 M OPERATING CASH FLOW
17.62%
-18.5 M INVESTING CASH FLOW
-47.35%
-3.28 M FINANCING CASH FLOW
72.35%
Balance Sheet Decomposition LivaNova PLC
image
Current Assets 988 M
Cash & Short-Term Investments 267 M
Receivables 215 M
Other Current Assets 507 M
Non-Current Assets 1.44 B
Long-Term Investments 22.8 M
PP&E 205 M
Other Non-Current Assets 1.21 B
Current Liabilities 335 M
Accounts Payable 80.8 M
Short-Term Debt 26.5 M
Other Current Liabilities 228 M
Non-Current Liabilities 817 M
Long-Term Debt 614 M
Other Non-Current Liabilities 203 M
EFFICIENCY
Earnings Waterfall LivaNova PLC
image
Revenue 1.15 B
Cost Of Revenue 382 M
Gross Profit 771 M
Operating Expenses 844 M
Operating Income -68.5 M
Other Expenses -86 M
Net Income 17.5 M
RATIOS
66.86% GROSS MARGIN
66.86%
-5.94% OPERATING MARGIN
-5.94%
1.52% NET MARGIN
1.52%
1.37% ROE
1.37%
0.72% ROA
0.72%
0.80% ROIC
0.80%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis LivaNova PLC
image
Net Income 17.5 M
Depreciation & Amortization 60.9 M
Capital Expenditures -35 M
Stock-Based Compensation 36.4 M
Change in Working Capital -34.6 M
Others 113 M
Free Cash Flow 39.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets LivaNova PLC
image
Wall Street analysts predict an average 1-year price target for LIVN of $68 , with forecasts ranging from a low of $65 to a high of $72 .
LIVN Lowest Price Target Wall Street Target
65 USD 24.76%
LIVN Average Price Target Wall Street Target
68 USD 30.52%
LIVN Highest Price Target Wall Street Target
72 USD 38.20%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership LivaNova PLC
image
Sold
0-3 MONTHS
69.9 K USD 1
3-6 MONTHS
3.4 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 11, 2024
Sell 69.9 K USD
Bianchi Francesco
Director
- 1500
46.58 USD
5 months ago
Jun 03, 2024
Sell 3.28 M USD
Moore Daniel Jeffrey
Director
- 54578
60.075 USD
5 months ago
Jun 03, 2024
Sell 125 K USD
Moore Daniel Jeffrey
Director
- 2045
61.086 USD
1 year ago
Mar 30, 2023
Sell 94.5 K USD
McDonald Damien
CEO
- 2220
42.55 USD
1 year ago
Dec 15, 2022
Sell 121 K USD
McDonald Damien
CEO
- 2220
54.56 USD
2 years ago
Apr 01, 2022
Sell 83.4 K USD
Moore Daniel Jeffrey
director:
- 1000
83.416 USD
2 years ago
Mar 29, 2022
Sell 227 K USD
McDonald Damien
CEO
- 2784
81.5 USD
2 years ago
Mar 02, 2022
Sell 80 K USD
Moore Daniel Jeffrey
director:
- 1000
80 USD
2 years ago
Feb 25, 2022
Sell 80 K USD
Moore Daniel Jeffrey
Director
- 1000
80 USD
2 years ago
Jan 03, 2022
Sell 85.9 K USD
Moore Daniel Jeffrey
Director
- 1000
85.9341 USD
2 years ago
Dec 13, 2021
Sell 227 K USD
McDonald Damien
CEO
- 2784
81.5 USD
2 years ago
Dec 01, 2021
Sell 81.7 K USD
Moore Daniel Jeffrey
Director
- 1000
81.734 USD
3 years ago
Nov 10, 2021
Sell 58.5 K USD
Novak Alfred J
Director
- 644
90.7659 USD
3 years ago
Nov 11, 2021
Sell 208 K USD
Novak Alfred J
Director
- 2337
89.1729 USD
3 years ago
Nov 10, 2021
Bought 90.4 K USD
KOZY WILLIAM A
Director
+ 1000
90.4282 USD
3 years ago
Nov 03, 2021
Sell 85.2 K USD
Moore Daniel Jeffrey
Director
- 1000
85.25 USD
3 years ago
Oct 01, 2021
Sell 80 K USD
Moore Daniel Jeffrey
Director
- 1000
80 USD
3 years ago
Sep 01, 2021
Sell 82.4 K USD
Moore Daniel Jeffrey
Director
- 1000
82.4015 USD
3 years ago
Aug 02, 2021
Sell 86.4 K USD
Moore Daniel Jeffrey
Director
- 1000
86.3886 USD
3 years ago
Jun 29, 2021
Sell 84.2 K USD
Moore Daniel Jeffrey
Director
- 1000
84.2 USD
3 years ago
May 18, 2021
Sell 84.8 K USD
Dolci Marco
SVP Global Operations, R&D
- 1019
83.2259 USD
3 years ago
May 18, 2021
Sell 602 K USD
Dolci Marco
SVP Global Operations, R&D
- 7259
82.8654 USD
7. News
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. businesswire.com - 5 days ago
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com - 1 week ago
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 week ago
Best Momentum Stocks to Buy for November 7th KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024. zacks.com - 1 week ago
New Strong Buy Stocks for November 7th MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. zacks.com - 1 week ago
Best Value Stocks to Buy for November 7th JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024. zacks.com - 1 week ago
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today. seekingalpha.com - 2 weeks ago
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. zacks.com - 2 weeks ago
LivaNova Reports Third-Quarter 2024 Results LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. businesswire.com - 2 weeks ago
LivaNova: Economics Should Start Making Sustained Improvements LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. seekingalpha.com - 4 weeks ago
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. benzinga.com - 1 month ago
LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today. seekingalpha.com - 3 months ago
8. Profile Summary

LivaNova PLC LIVN

image
COUNTRY GB
INDUSTRY Medical - Devices
MARKET CAP $ 2.83 B
Dividend Yield 0.00%
Description LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Contact 20 Eastbourne Terrace, London, W2 6LG https://www.livanova.com
IPO Date Oct. 19, 2015
Employees 2900
Officers Deanna Wilke Vice President of Corporate Communications Ahmet Tezel Ph.D. Chief Innovation Officer Mr. Franco Poletti President of Cardiopulmonary Business Unit Ms. Stephanie Bolton President of Global Epilepsy Mr. Vladimir A. Makatsaria Chief Executive Officer & Director Ms. Lindsey Little Senior Director of Investor Relations Mr. John Webb Vice President of Sleep Apnea and Epilepsy Mr. Matthew Joseph Dodds III Senior Vice President of Corporate Development & IT Mr. Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement Mr. Michael D. Hutchinson Senior Vice President, Chief Legal Officer & Company Secretary